Eris Lifesciences zooms on acquiring 51% stake in Swiss Parenterals
Eris Lifesciences is currently trading at Rs. 910.00, up by 53.20 points or 6.21% from its previous closing of Rs. 856.80 on the BSE.
The scrip opened at Rs. 879.95 and has touched a high and low of Rs. 923.45 and Rs. 858.70 respectively. So far 47924 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 971.00 on 09-Nov-2023 and a 52 week low of Rs. 550.90 on 17-Mar-2023.
Last one week high and low of the scrip stood at Rs. 942.85 and Rs. 845.90 respectively. The current market cap of the company is Rs. 12364.97 crore.
The promoters holding in the company stood at 54.90%, while Institutions and Non-Institutions held 27.70% and 17.41% respectively.
Eris Lifesciences has completed acquisition of 51% equity stake in Swiss Parenterals. On February 13, 2024, the company had executed Share Purchase and Shareholders’ agreement for acquisition of 51% equity stake in Swiss Parenterals. The cost of acquisition is Rs 637.50 crore.
Eris Lifesciences develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives.
